{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:46:35Z","timestamp":1780580795690,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["JP17KK0169"],"award-info":[{"award-number":["JP17KK0169"]}]},{"name":"JSPS KAKENHI","award":["JP21H03111"],"award-info":[{"award-number":["JP21H03111"]}]},{"name":"JSPS KAKENHI","award":["JP22K19626"],"award-info":[{"award-number":["JP22K19626"]}]},{"name":"JSPS KAKENHI","award":["JP22H03104"],"award-info":[{"award-number":["JP22H03104"]}]},{"name":"JSPS KAKENHI","award":["JP20K18784"],"award-info":[{"award-number":["JP20K18784"]}]},{"name":"JSPS KAKENHI","award":["JP22K08455"],"award-info":[{"award-number":["JP22K08455"]}]},{"DOI":"10.13039\/100017682","name":"Japanese Society of Hematology","doi-asserted-by":"publisher","award":["20247"],"award-info":[{"award-number":["20247"]}],"id":[{"id":"10.13039\/100017682","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005623","name":"University of Tokushima","doi-asserted-by":"publisher","award":["1803003"],"award-info":[{"award-number":["1803003"]}],"id":[{"id":"10.13039\/501100005623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005623","name":"University of Tokushima","doi-asserted-by":"publisher","award":["2202003"],"award-info":[{"award-number":["2202003"]}],"id":[{"id":"10.13039\/501100005623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Proteasome inhibitors (PIs) can preferentially restore bone in bone-defective lesions of patients with multiple myeloma (MM) who respond favorably to these drugs. Most prior in vitro studies on PIs used continuous exposure to low PI concentrations, although pharmacokinetic analysis in patients has shown that serum concentrations of PIs change in a pulsatile manner. In the present study, we explored the effects of pulsatile treatment with PIs on bone metabolism to simulate in vivo PI pharmacokinetics. Pulsatile treatment with bortezomib, carfilzomib, or ixazomib induced MM cell death but only marginally affected the viability of osteoclasts (OCs) with F-actin ring formation. Pulsatile PI treatment suppressed osteoclastogenesis in OC precursors and bone resorption by mature OCs. OCs robustly enhanced osteoblastogenesis in cocultures with OCs and MC3T3-E1 pre-osteoblastic cells, indicating OC-mediated coupling to osteoblastogenesis. Importantly, pulsatile PI treatment did not impair robust OC-mediated osteoblastogenesis. These results suggest that PIs might sufficiently reduce MM cell-derived osteoblastogenesis inhibitors to permit OC-driven bone formation coupling while suppressing OC differentiation and activity in good responders to PIs. OC-mediated coupling to osteoblastogenesis appears to be a predominant mechanism for preferential occurrence of bone regeneration at sites of osteoclastic bone destruction in good responders.<\/jats:p>","DOI":"10.1007\/s12185-023-03601-2","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T14:41:44Z","timestamp":1681224104000},"page":"88-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors"],"prefix":"10.1007","volume":"118","author":[{"given":"Emiko","family":"Nakaue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-5488","authenticated-orcid":false,"given":"Jumpei","family":"Teramachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Tenshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Higa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiko","family":"Sogabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Oura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyo","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Sumitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Maruhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"issue":"6","key":"3601_CR1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/1078-0432.Ccr-10-1804","volume":"17","author":"N Raje","year":"2011","unstructured":"Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res. 2011;17(6):1278\u201386. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-1804.","journal-title":"Clin Cancer Res"},{"key":"3601_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jdsr.2021.08.006","volume":"57","author":"M Hiasa","year":"2021","unstructured":"Hiasa M, Harada T, Tanaka E, Abe M. Pathogenesis and treatment of multiple myeloma bone disease. Jpn Dent Sci Rev. 2021;57:164\u201373. https:\/\/doi.org\/10.1016\/j.jdsr.2021.08.006.","journal-title":"Jpn Dent Sci Rev"},{"key":"3601_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174441","author":"T Harada","year":"2021","unstructured":"Harada T, Hiasa M, Teramachi J, Abe M. Myeloma-bone interaction: a vicious cycle via TAK1-PIM2 signaling. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13174441.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"3601_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.abb.2008.03.027","volume":"473","author":"K Matsuo","year":"2008","unstructured":"Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys. 2008;473(2):201\u20139. https:\/\/doi.org\/10.1016\/j.abb.2008.03.027.","journal-title":"Arch Biochem Biophys"},{"key":"3601_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.semcdb.2021.10.008","volume":"123","author":"MM Durdan","year":"2022","unstructured":"Durdan MM, Azaria RD, Weivoda MM. Novel insights into the coupling of osteoclasts and resorption to bone formation. Semin Cell Dev Biol. 2022;123:4\u201313. https:\/\/doi.org\/10.1016\/j.semcdb.2021.10.008.","journal-title":"Semin Cell Dev Biol"},{"issue":"26","key":"3601_CR6","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349(26):2483\u201394. https:\/\/doi.org\/10.1056\/NEJMoa030847.","journal-title":"N Engl J Med"},{"issue":"9","key":"3601_CR7","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","volume":"106","author":"T Oshima","year":"2005","unstructured":"Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005;106(9):3160\u20135. https:\/\/doi.org\/10.1182\/blood-2004-12-4940.","journal-title":"Blood"},{"issue":"3","key":"3601_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1359\/jbmr.081104","volume":"24","author":"DJ Heath","year":"2009","unstructured":"Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24(3):425\u201336. https:\/\/doi.org\/10.1359\/jbmr.081104.","journal-title":"J Bone Miner Res"},{"issue":"26","key":"3601_CR9","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","volume":"129","author":"MM McDonald","year":"2017","unstructured":"McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood. 2017;129(26):3452\u201364. https:\/\/doi.org\/10.1182\/blood-2017-03-773341.","journal-title":"Blood"},{"issue":"4","key":"3601_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1200\/jco.2011.37.8919","volume":"30","author":"KC Anderson","year":"2012","unstructured":"Anderson KC. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30(4):445\u201352. https:\/\/doi.org\/10.1200\/jco.2011.37.8919.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3601_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4(5):349\u201360. https:\/\/doi.org\/10.1038\/nrc1361.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3601_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P P\u00e9rez-Gal\u00e1n","year":"2006","unstructured":"P\u00e9rez-Gal\u00e1n P, Rou\u00e9 G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107(1):257\u201364. https:\/\/doi.org\/10.1182\/blood-2005-05-2091.","journal-title":"Blood"},{"issue":"1","key":"3601_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/leu.2015.190","volume":"30","author":"EE Fink","year":"2016","unstructured":"Fink EE, Mannava S, Bagati A, Bianchi-Smiraglia A, Nair JR, Moparthy K, et al. Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells. Leukemia. 2016;30(1):104\u201311. https:\/\/doi.org\/10.1038\/leu.2015.190.","journal-title":"Leukemia"},{"issue":"1","key":"3601_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","volume":"131","author":"M Zangari","year":"2005","unstructured":"Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005;131(1):71\u20133. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05733.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"3601_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1532\/ijh97.07030","volume":"86","author":"S Ozaki","year":"2007","unstructured":"Ozaki S, Tanaka O, Fujii S, Shigekiyo Y, Miki H, Choraku M, et al. Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol. 2007;86(2):180\u20135. https:\/\/doi.org\/10.1532\/ijh97.07030.","journal-title":"Int J Hematol"},{"issue":"6","key":"3601_CR16","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1600-0609.2011.01602.x","volume":"86","author":"M Zangari","year":"2011","unstructured":"Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, et al. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011;86(6):484\u20137. https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01602.x.","journal-title":"Eur J Haematol"},{"key":"3601_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bone.2016.02.019","volume":"86","author":"M Zangari","year":"2016","unstructured":"Zangari M, Suva LJ. The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone. 2016;86:131\u20138. https:\/\/doi.org\/10.1016\/j.bone.2016.02.019.","journal-title":"Bone"},{"issue":"12","key":"3601_CR18","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3324\/haematol.13285","volume":"93","author":"P Moreau","year":"2008","unstructured":"Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica. 2008;93(12):1908\u201311. https:\/\/doi.org\/10.3324\/haematol.13285.","journal-title":"Haematologica"},{"issue":"22","key":"3601_CR19","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1158\/1078-0432.Ccr-09-0822","volume":"15","author":"OA O'Connor","year":"2009","unstructured":"O\u2019Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009;15(22):7085\u201391. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-0822.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3601_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/bcj.2014.71","volume":"4","author":"SE Assouline","year":"2014","unstructured":"Assouline SE, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, et al. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed\/refractory lymphoma. Blood Cancer J. 2014;4(10):251. https:\/\/doi.org\/10.1038\/bcj.2014.71.","journal-title":"Blood Cancer J"},{"issue":"4","key":"3601_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/bjh.14388","volume":"180","author":"J Teramachi","year":"2018","unstructured":"Teramachi J, Hiasa M, Oda A, Harada T, Nakamura S, Amachi R, et al. Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma. Br J Haematol. 2018;180(4):581\u20135. https:\/\/doi.org\/10.1111\/bjh.14388.","journal-title":"Br J Haematol"},{"issue":"9","key":"3601_CR22","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/jcb.25151","volume":"116","author":"H Shinohara","year":"2015","unstructured":"Shinohara H, Teramachi J, Okamura H, Yang D, Nagata T, Haneji T. Double stranded RNA-dependent protein kinase is necessary for TNF-\u03b1-induced osteoclast formation in vitro and in vivo. J Cell Biochem. 2015;116(9):1957\u201367. https:\/\/doi.org\/10.1002\/jcb.25151.","journal-title":"J Cell Biochem"},{"key":"3601_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062893","author":"A Watahiki","year":"2021","unstructured":"Watahiki A, Hoshikawa S, Chiba M, Egusa H, Fukumoto S, Inuzuka H. Deficiency of lipin2 results in enhanced NF-\u03baB signaling and osteoclast formation in RAW-D murine macrophages. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22062893.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3601_CR24","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3324\/haematol.2019.234476","volume":"106","author":"J Teramachi","year":"2021","unstructured":"Teramachi J, Tenshin H, Hiasa M, Oda A, Bat-Erdene A, Harada T, et al. TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma. Haematologica. 2021;106(5):1401\u201313. https:\/\/doi.org\/10.3324\/haematol.2019.234476.","journal-title":"Haematologica"},{"issue":"2","key":"3601_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cmet.2006.05.012","volume":"4","author":"C Zhao","year":"2006","unstructured":"Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006;4(2):111\u201321. https:\/\/doi.org\/10.1016\/j.cmet.2006.05.012.","journal-title":"Cell Metab"},{"issue":"52","key":"3601_CR26","doi-asserted-by":"publisher","first-page":"20764","DOI":"10.1073\/pnas.0805133106","volume":"105","author":"L Pederson","year":"2008","unstructured":"Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt\/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA. 2008;105(52):20764\u20139. https:\/\/doi.org\/10.1073\/pnas.0805133106.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3601_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","volume":"110","author":"N Giuliani","year":"2007","unstructured":"Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007;110(1):334\u20138. https:\/\/doi.org\/10.1182\/blood-2006-11-059188.","journal-title":"Blood"},{"issue":"2","key":"3601_CR28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/jci33102","volume":"118","author":"S Mukherjee","year":"2008","unstructured":"Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, et al. Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008;118(2):491\u2013504. https:\/\/doi.org\/10.1172\/jci33102.","journal-title":"J Clin Invest"},{"issue":"18","key":"3601_CR29","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1182\/blood-2008-08-174300","volume":"113","author":"YW Qiang","year":"2009","unstructured":"Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin\/TCF signaling. Blood. 2009;113(18):4319\u201330. https:\/\/doi.org\/10.1182\/blood-2008-08-174300.","journal-title":"Blood"},{"issue":"1","key":"3601_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12185-013-1367-z","volume":"98","author":"S Nakamura","year":"2013","unstructured":"Nakamura S, Miki H, Kido S, Nakano A, Hiasa M, Oda A, et al. Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib. Int J Hematol. 2013;98(1):66\u201373. https:\/\/doi.org\/10.1007\/s12185-013-1367-z.","journal-title":"Int J Hematol"},{"issue":"6","key":"3601_CR31","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/jbmr.2789","volume":"31","author":"H Eda","year":"2016","unstructured":"Eda H, Santo L, Wein MN, Hu DZ, Cirstea DD, Nemani N, et al. Regulation of sclerostin expression in multiple myeloma by Dkk-1: A potential therapeutic strategy for myeloma bone disease. J Bone Miner Res. 2016;31(6):1225\u201334. https:\/\/doi.org\/10.1002\/jbmr.2789.","journal-title":"J Bone Miner Res"},{"key":"3601_CR32","doi-asserted-by":"publisher","first-page":"9661200","DOI":"10.1155\/2021\/9661200","volume":"2021","author":"Y Fang","year":"2021","unstructured":"Fang Y, Liu Y, Zhao Z, Lu Y, Shen X, Zhu T, et al. Bortezomib rescues ovariectomy-induced bone loss via SMURF-mediated ubiquitination pathway. Oxid Med Cell Longev. 2021;2021:9661200. https:\/\/doi.org\/10.1155\/2021\/9661200.","journal-title":"Oxid Med Cell Longev"},{"issue":"9","key":"3601_CR33","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","volume":"110","author":"DJ Kuhn","year":"2007","unstructured":"Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281\u201390. https:\/\/doi.org\/10.1182\/blood-2007-01-065888.","journal-title":"Blood"},{"key":"3601_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040929","author":"M Ashtar","year":"2020","unstructured":"Ashtar M, Tenshin H, Teramachi J, Bat-Erdene A, Hiasa M, Oda A, et al. The roles of ROS generation in RANKL-induced osteoclastogenesis: suppressive effects of febuxostat. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12040929.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3601_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/leu.2014.147","volume":"29","author":"M Hiasa","year":"2015","unstructured":"Hiasa M, Teramachi J, Oda A, Amachi R, Harada T, Nakamura S, et al. Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. Leukemia. 2015;29(1):207\u201317. https:\/\/doi.org\/10.1038\/leu.2014.147.","journal-title":"Leukemia"},{"issue":"11","key":"3601_CR36","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/jbmr.1695","volume":"27","author":"B Langdahl","year":"2012","unstructured":"Langdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27(11):2251\u20138. https:\/\/doi.org\/10.1002\/jbmr.1695.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"3601_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00223-015-0051-0","volume":"98","author":"T le Duong","year":"2016","unstructured":"le Duong T, Leung AT, Langdahl B. Cathepsin K inhibition: a new mechanism for the treatment of osteoporosis. Calcif Tissue Int. 2016;98(4):381\u201397. https:\/\/doi.org\/10.1007\/s00223-015-0051-0.","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"3601_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1210\/er.2015-1114","volume":"38","author":"MT Drake","year":"2017","unstructured":"Drake MT, Clarke BL, Oursler MJ, Khosla S. Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned. Endocr Rev. 2017;38(4):325\u201350. https:\/\/doi.org\/10.1210\/er.2015-1114.","journal-title":"Endocr Rev"},{"issue":"2","key":"3601_CR39","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1172\/jci64840","volume":"123","author":"S Lotinun","year":"2013","unstructured":"Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, L\u00fcth A, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013;123(2):666\u201381. https:\/\/doi.org\/10.1172\/jci64840.","journal-title":"J Clin Invest"},{"issue":"3","key":"3601_CR40","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/s1470-2045(18)30072-x","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, Shimizu K, Garc\u00eda-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370\u201381. https:\/\/doi.org\/10.1016\/s1470-2045(18)30072-x.","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03601-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03601-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03601-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T17:21:04Z","timestamp":1687368064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03601-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3601"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03601-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"assertion":[{"value":"4 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.A. received research funding from Chuagai Pharmaceutical, Sanofi K.K., Kyowa Kirin, Janssen Pharmaceutical K.K., Takeda Pharmaceutical, Teijin Pharma, and Ono Pharmaceutical, and honoraria from Daiichi Sankyo Co. All other authors have no competing financial interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}